Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

ABSTRACT:

Purpose

Frontline ovarian cancer treatment protocols involving bevacizumab, poly (ADP-ribose) polymerase inhibitors, and PD-1/PD-L1 inhibitors have failed to improve overall survival (OS) in patients with homologous recombination-proficient (HRP) tumors. To determine mechanistic mutation signatures associated with OS advantage, we constructed a whole-exome sequencing bioinformatic pipeline assay to analyze all 91 patients enrolled in the double-blind randomized placebo-controlled phase II VITAL trial.

Methods

We hypothesized that patients with stage IIIb-IV ovarian cancer who have HRP profile and high clonal tumor mutation burden (cTMB-H) will achieve greater response when undergoing maintenance therapy with gemogenovatucel-T. Our primary objective was assessment of OS using

SUBMITTER: Coleman RL 

PROVIDER: S-EPMC12834266 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature